Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence

References

• Jasovsky D, Littmann J, Zorzet A, Cars O. Antimicrobial resistance-a threat to the world’s sustainable development. Ups J Med Sci. 2016;121(3):159–164. doi:10.1080/03009734.2016.119590027416324
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Healthcare Quality Promotion (DHQP), Antibiotic/Antimicrobial Resistance (AR/AMR). Biggest threats and data. Available from: https://www.cdc.gov/drugresistance/biggest_threats.html. Accessed 825, 2019.
   Google Scholar
• Gajdács M. The continuing threat of methicillin-resistant staphylococcus aureus. Antibiotics. 2019;8(2):52. doi:10.3390/antibiotics8020052
   Web of Science ®Google Scholar
• World Health Organization. Antimicrobial resistance key facts. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed 825, 2019.
   Google Scholar
• Gajdács M, Albericio F. Antibiotic resistance: from the bench to patients. Antibiotics. 2019;8(3):129. doi:10.3390/antibiotics8030129
   Web of Science ®Google Scholar
• Yu Y, Fei A. Atypical pathogen infection in community-acquired pneumonia. Biosci Trends. 2016;10(1):7–13. doi:10.5582/bst.2016.0102126961211
   PubMed Web of Science ®Google Scholar
• Huong Ple T, Hien PT, Lan NT, Binh TQ, Tuan DM, Anh DD. First report on prevalence and risk factors of severe atypical pneumonia in vietnamese children aged 1–15 years. BMC Public Health. 2014;14:1304. doi:10.1186/1471-2458-14-130425524126
   PubMed Web of Science ®Google Scholar
• Gajdács M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24(5):892. doi:10.3390/molecules24050892
   PubMed Web of Science ®Google Scholar
• De Souza NJ, Gupte SV, Deshpande PK, et al. A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant staphylococcus aureus. J Med Chem. 2005;48(16):5232–5242. doi:10.1021/jm050035f16078842
   PubMed Web of Science ®Google Scholar
• Bhagwat SS, McGhee P, Kosowska-Shick K, Patel MV, Appelbaum PC. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob Agents Chemother. 2009;53(2):811–813. doi:10.1128/AAC.01150-0819029326
   PubMed Web of Science ®Google Scholar
• Dubois J, Dubois M. In vitro extracellular and intracellular activity of Levonadifloxacin (WCK 771) against S. aureus. Abstract Friday-AAR-785. Presented at 4th annual American Society for Microbiology General Meeting (MICROBE); 2019; San Francisco, CA.
   Google Scholar
• Upadhyay DJ, Patel MV, Gupte SV, et al. WCK 771A-an investigational fluoroquinolone (FQ) with unusual property of retaining potency in acidic medium, human urine and efficacy in mouse pyelonephritis model, abstract F-538. Presented at 41st Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago.
   Google Scholar
• Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53(10):1565–1574. doi:10.1021/bi500056424576155
   PubMed Web of Science ®Google Scholar
• Bhagwat SS, Mundkur LA, Gupte SV, Patel MV, Khorakiwala HF. The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. Antimicrob Agents Chemother. 2006;50(11):3568–3579. doi:10.1128/AAC.00641-0616940059
   PubMed Web of Science ®Google Scholar
• Bhagwat SS, Mundkur L, Gupte SV, Khorakiwala HF, Patel MV. WCK 771 selects first step mutants of s. aureus in dna gyrase. Abstract C1-1409. Presented at 45th Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 21–24; 2005; New Orleans, LA.
   Google Scholar
• Jacobs MR, Bajaksouzian S, Windau A, et al. In vitro activity of the new quinolone WCK 771 against staphylococci. Antimicrob Agents Chemother. 2004;48(9):3338–3342. doi:10.1128/AAC.48.9.3338-3342.200415328094
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the hershey medical center. J Antimicrob Chemother. 2003;52(5):864–868. doi:10.1093/jac/dkg45714563898
   PubMed Web of Science ®Google Scholar
• McHgee P, Appelbaum PC Comparative activity of WCK 771 against S. aureus with raised vancomycin and daptomycin mics and other resistotypes. Abstract F1-2129.
   Google Scholar
• Flamm RK, Farrell DJ, Sader HS, Rhomberg PR, Jones RN. In vitro activity of WCK 771, a benzoquinolizine fluoroquinolone (levonadifloxacin) when tested against contemporary gram-positive and -negative bacteria from a global surveillance program. Sunday-456. Presented at 1st annual American Society for Microbiology General Meeting (MICROBE); June 16–20; 2016; Boston, Massachusetts.
   Google Scholar
• Hackel M, Bhagwat S, Kanade H, Joshi P, Patel M, Sahm D. In vitro activity of WCk771, a new benzoquinolizine quinolone in development, against key bacterial groups from the USA and Europe. F-1196. Available from: http://wockhardtdiscovery.com/wp-content/plugins/wp-pdf-stamper/stamped-files/F-1196_5702576cc94a1_e.pdf. Accessed 1126, 2019.
   Google Scholar
• Xue G, Crabb DM, Xiao L, Liu Y, Waites KB. In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms. Antimicrob Agents Chemother. 2018;62(11):e01348–18. doi:10.1128/AAC.01348-1830104279
   PubMed Web of Science ®Google Scholar
• Kohlhoff S, Huerta N, Hammerschlag M. In vitro activity of levonadifloxacin (WCK 771) against chlamydia pneumoniae. Antimicrob Agents Chemother. 2019;63(8):e01048–19. doi:10.1128/AAC.01048-1931160287
   PubMed Web of Science ®Google Scholar
• Peric M, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother. 2004;48(8):3188–3192. doi:10.1128/AAC.48.8.3188-3192.200415273148
   PubMed Web of Science ®Google Scholar
• Heine HS, Demons ST, Miller LL, et al. In vitro activity of WCK771, a broad-spectrum anti-MRSA benzoquinolizine subclass of quinolone against five biodefense bacterial pathogens. Abstract F-1188. Available from: http://wockhardtdiscovery.com/wp-content/plugins/wp-pdf-stamper/stamped-files/F-1188_5702595e2d2aa_e.pdf. Accessed 1126, 2019.
   Google Scholar
• Patel M, Gupte S, Upadhyay D, et al. WCK 771-predictive MRSA eradication through in vitro pharmacokinetic model (IVPM) based on human PK. Abstract A 1165. Presented at 43rd Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003; Chicago.
   Google Scholar
• Appelbaum PC, Pankuch GA, Bozdogan B, et al. Activity of the new quinolone WCK 771 against pneumococci. Clin Microbiol Infect. 2005;11(1):9–14. doi:10.1111/j.1469-0691.2004.01017.x
   PubMed Web of Science ®Google Scholar
• Al-Lahham A, De Souza NJ, Patel M, Rene Reinert R. Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. J Antimicrob Chemother. 2005;56(6):1130–1133. doi:10.1093/jac/dki36116239291
   PubMed Web of Science ®Google Scholar
• Pankuch GA, Jacobs MR, Khorakiwala H, De Souza N, Patel M, Appelbaum PC. Anti-pneumococcal activities of WCK 771 and WCK 919 (two new quinolones) compared to 12 other agents against 177 quinolone susceptible pneumococci, abstract F-1194. Presented at 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago US.
   Google Scholar
• Gupte S, Patel M, Jafri M, Narayanan P, Khorakiwala A. WCK 771- gram negative breakpoint determination through IVPM (in vitro pharmacokinetic model) study based on human pharmacokinetic parameters. Abstract A-440. Presented at 45th Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005; Washington DC.
   Google Scholar
• Jacobs MR, Appelbaum PC. Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother. 2006;7:1957–1966. doi:10.1517/14656566.7.14.195717020421
   PubMed Web of Science ®Google Scholar
• Dubois J, Dubois M. In vitro activity of levonadifloxacin against legionella pneumophilia, abstract P0620. Presented at 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID); April 21–24; 2018; Spain.
   Google Scholar
• Tellis M, Joseph J, Khande H, Bhagwat S, Patel M. In vitro bactericidal activity of Levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. J Med Microbial. 2019;68(8):1129–1136. doi:10.1099/jmm.0.000999
   PubMed Web of Science ®Google Scholar
• Hackel M, Bhagwat S, Satav J, et al. Determination of tier 1 quality control ranges for WCK 771. Abstract F-1194, ICAAC 2015 55th Inter-science Conference on Antimicrobial Agents and Chemotherapy September 17-21; 2015; San Diego, CA.
   Google Scholar
• Performance CLSI. Standards for Antimicrobial Susceptibility Testing, 26th Ed. CLSI Supplement M100S. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
   Google Scholar
• Hackel M, Bhagwat S, Palwe S, Patel M, Sahm D. Determination of disk diffusion zone and broth dilution MIC for WCK 771. Abstract F-1195, ICAAC 2015 55th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17–21; 2015; San Diego, CA.
   Google Scholar
• Gupte SV, Patel MV, Agarwal SK, et al. The impact of NorA mediated efflux on in vitro and in vivo anti-Staphylococcal efficacy of an investigational fluoroquinolone (FQ) WCK 771 A and other FQs. Abstract F-537. 41st Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); December 16–19; 2001; Chicago.
   Google Scholar
• Patel MV, Appelbaum PC, Jacobs MR, et al. WCK 771 A - an investigational anti-staphylococcal fluoroquinolone (FQ) with strong bactericidal activity against low- and high-density cultures. Abstract F – 536. Presented at 4st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago.
   Google Scholar
• Upadhyay DJ, Patel MV, Gupte SK, et al. WCK 771 A-an investigational anti-MRSA fluoroquinoone (FQ) with potent concentration independent cidal action and an unusual ability to kill slow growing Staphylococci. Abstract F – 534. Presented at ICAAC; 2001; Chicago.
   Google Scholar
• Patel MV, De Souza NJ, Gupte SV, et al. Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. Antimicrob Agents Chemother. 2004;48(12):4754–4761. doi:10.1128/AAC.48.12.4754-4761.200415561853
   PubMed Web of Science ®Google Scholar
• Gupte S, Patel M, Agarwal S, et al. In vitro and in vivo efficacy of an investigational fluoroquinolone (FQ) WCK 771 A against pneumococci. Abstract F-535, Presented at Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago.
   Google Scholar
• Patel M, Gupte S, Agarwal S, et al. In vivo efficacy of fluoroquinolone (FQ) WCK 771 A in thigh infections caused by MSSA and MRSA., Abstract F-540. Presented at Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago.
   Google Scholar
• Bhagwat S, Periasamy H, Takalkar S, et al. In vivo pharmacokinetic/pharmacodynamic targets of levonadifloxacin against Staphylococcus aureus in a neutropenic murine lung infection model. Antimicrob Agents Chemother. 2019;63:. doi:10.1128/AAC.00909-19
   Web of Science ®Google Scholar
• Patel M, Gupte S, Shetty N, et al. WCK 771- an investigational FQ with high intravenous tolerability. Abstract F-431, Presented at 43rd Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003; Chicago.
   Google Scholar
• Niu J, Ivaturi V, Gobburu J, Chugh R, Bhatia A. Pharmacokinetics of levonadifloxacin administered as intravenous WCK 771 and oral WCK 2349 in healthy Indian male adults. Abstract A-032, 55th ICAAC; 2015.
   Google Scholar
• Chugh R, Lakdavala F, Bhatia A. Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK 2349. Abstract P1268. 26th Eur congr clin microbial infect dis, Amsterdam, Netherlands. European Society of Clinical Microbiology and Infectious Diseases; 2016; Basel, Switzerland.
   Google Scholar
• Mehrotra S, Ivaturi V, Gobburu J, Chugh R, Bhatia A. Pharmacokinetics of intravenous WCK 771 in healthy US adults. Abstract A-031, Presented at 55th ICAAC; 2015.
   Google Scholar
• Chugh R, Lakdavala F, Bhagwat S, Patel M, Bhatia A. Food effect and absolute bioavailability study of WCK 2349 and WCK 771 in healthy adult human volunteer in US. Abstract A-039. Presented at 55th ICAAC; 2015.
   Google Scholar
• Preston RA, Chugh R, Mastim M, Shukla U, Bhatia A. Single-center evaluation of the pharmacokinetics and safety of the novel fluoroquinolone WCK 2349 in hepatic impairment. Abstract P1270. 26th Eur Congr Clin Microbial Infect Dis, Amsterdam, Netherlands; 2016; European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
   Google Scholar
• Rodvold KA, Gotfried MH, Chugh R, et al. Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother. 2018;62(3):e02297–2317. doi:10.1128/AAC.01089-1829263070
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology. 2011;120(2):103–110. doi:10.1159/00033444122156660
   PubMed Web of Science ®Google Scholar
• Mason JW, Chugh R, Lakdavala F, Bhatia A. Electrocardiographic effects of WCK 2349. Abstract P 1269. 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9th–12th; 2016; Amsterdam Available from: https://www.morressier.com/article/electrocardiographic-effects-wck-2349/56d6be7ad462b80296c97cf4. Accessed 1126, 2019.
   Google Scholar
• Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic effects of a supratherapeutic dose of WCK 2349, a benzoquinolizine fluoroquinolone. Clin Transl Sci. 2019;12(1):47–52. doi:10.1111/cts.v12.130369076
   PubMed Web of Science ®Google Scholar